My recent switch from Bristol Myers into Merck looks even better

On January 11th I sent out a blog recommending a switch out of Bristol Myers into Merck, based on the latter’s fast track FDA approval for its lung cancer drug, Keytryda.

Yesterday afternoon Bristol Myers indicated that it will not continue to pursue an FDA fast track approval for its first time lung cancer combination of its Opdivo and Yervay drug.

The share price of Bristol Myers dropped nearly 10% on this news, while Merck’s climbed over 2%.

This news makes Merck look even better as it now will have a significant advantage over its competitors in the very lucrative lung cancer area.

Posted in Blog Post.

Leave a Reply